# Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients

Study · id `cardio:ct-nct03476616` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03476616](<https://clinicaltrials.gov/study/NCT03476616>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03476616

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

## Technical summary

Registry record NCT03476616. Randomized; no masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2025-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT03476616, source copy `cardio:ctgov-nct03476616-2025-07-31`, retrieved 2026-10-26)
- Started: 2018-09-01 (actual) (ClinicalTrials.gov record NCT03476616, source copy `cardio:ctgov-nct03476616-2025-07-31`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT03476616, source copy `cardio:ctgov-nct03476616-2025-07-31`, retrieved 2026-10-26)
- Completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT03476616, source copy `cardio:ctgov-nct03476616-2025-07-31`, retrieved 2026-10-26)
- Countries: Greece (ClinicalTrials.gov record NCT03476616, source copy `cardio:ctgov-nct03476616-2025-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03476616-2025-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients
- Acronym: HEBRO
- Condition: Hypertension
- Condition: Obesity
- Intervention (Drug): Eplerenone (-based therapy) arm
- Intervention (Drug): Valsartan (-based therapy) arm
- Lead sponsor: Hippocration General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hippocration General Hospital (`cardio:org-hippocration-general-hospital`)

## Provenance

Content hash: 8913e3386451c6c8313dafdbfe6a4773a3032751dc574122df5b6aba1e89bb08
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
